Cargando…

HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis

Tumor-infiltrating T cell rescue by programmed cell death receptor-1 (PD-1)/PD-1 ligand-1 (PD-L1) immune checkpoint blockade is a recommended treatment for malignant diseases, including metastatic non-small-cell lung cancer (mNSCLC), malignant melanoma (MM), head and neck, kidney, and urothelial can...

Descripción completa

Detalles Bibliográficos
Autores principales: Correale, Pierpaolo, Saladino, Rita Emilena, Giannarelli, Diana, Sergi, Andrea, Mazzei, Maria Antonietta, Bianco, Giovanna, Giannicola, Rocco, Iuliano, Eleonora, Forte, Iris Maria, Calandruccio, Natale Daniele, Falzea, Antonia Consuelo, Strangio, Alessandra, Nardone, Valerio, Pastina, Pierpaolo, Tini, Paolo, Luce, Amalia, Caraglia, Michele, Caracciolo, Daniele, Mutti, Luciano, Tassone, Pierfrancesco, Pirtoli, Luigi, Giordano, Antonio, Tagliaferri, Pierosandro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564884/
https://www.ncbi.nlm.nih.gov/pubmed/32854442
http://dx.doi.org/10.3390/cells9091964
_version_ 1783595815468531712
author Correale, Pierpaolo
Saladino, Rita Emilena
Giannarelli, Diana
Sergi, Andrea
Mazzei, Maria Antonietta
Bianco, Giovanna
Giannicola, Rocco
Iuliano, Eleonora
Forte, Iris Maria
Calandruccio, Natale Daniele
Falzea, Antonia Consuelo
Strangio, Alessandra
Nardone, Valerio
Pastina, Pierpaolo
Tini, Paolo
Luce, Amalia
Caraglia, Michele
Caracciolo, Daniele
Mutti, Luciano
Tassone, Pierfrancesco
Pirtoli, Luigi
Giordano, Antonio
Tagliaferri, Pierosandro
author_facet Correale, Pierpaolo
Saladino, Rita Emilena
Giannarelli, Diana
Sergi, Andrea
Mazzei, Maria Antonietta
Bianco, Giovanna
Giannicola, Rocco
Iuliano, Eleonora
Forte, Iris Maria
Calandruccio, Natale Daniele
Falzea, Antonia Consuelo
Strangio, Alessandra
Nardone, Valerio
Pastina, Pierpaolo
Tini, Paolo
Luce, Amalia
Caraglia, Michele
Caracciolo, Daniele
Mutti, Luciano
Tassone, Pierfrancesco
Pirtoli, Luigi
Giordano, Antonio
Tagliaferri, Pierosandro
author_sort Correale, Pierpaolo
collection PubMed
description Tumor-infiltrating T cell rescue by programmed cell death receptor-1 (PD-1)/PD-1 ligand-1 (PD-L1) immune checkpoint blockade is a recommended treatment for malignant diseases, including metastatic non-small-cell lung cancer (mNSCLC), malignant melanoma (MM), head and neck, kidney, and urothelial cancer. Monoclonal antibodies (mAbs) against either PD-1 or PD-L1 are active agents for these patients; however, their use may be complicated by unpredictable immune-related adverse events (irAEs), including immune-related pneumonitis (IRP). We carried out a retrospective multi-institutional statistical analysis to investigate clinical and biological parameters correlated with IRP rate on a cohort of 256 patients who received real-world treatment with PD-1/PD-L1 blocking mAbs. An independent radiological review board detected IRP in 29 patients. We did not find statistical IRP rate correlation with gender, tumor type, specific PD-1 or PD-L1 blocking mAbs, radiation therapy, inflammatory profile, or different irAEs. A higher IRP risk was detected only in mNSCLC patients who received metronomic chemotherapy +/− bevacizumab compared with other treatments prior PD-1/PD-L1 blockade. Moreover, we detected a strong correlation among the IRP rate and germinal expression of HLA-B*35 and DRB1*11, alleles associated to autoimmune diseases. Our findings may have relevant implications in predicting the IRP rate in mNSCLC patients receiving PD-1/PD-L1 blockade and need to be validated on a larger patient series.
format Online
Article
Text
id pubmed-7564884
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-75648842020-10-26 HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis Correale, Pierpaolo Saladino, Rita Emilena Giannarelli, Diana Sergi, Andrea Mazzei, Maria Antonietta Bianco, Giovanna Giannicola, Rocco Iuliano, Eleonora Forte, Iris Maria Calandruccio, Natale Daniele Falzea, Antonia Consuelo Strangio, Alessandra Nardone, Valerio Pastina, Pierpaolo Tini, Paolo Luce, Amalia Caraglia, Michele Caracciolo, Daniele Mutti, Luciano Tassone, Pierfrancesco Pirtoli, Luigi Giordano, Antonio Tagliaferri, Pierosandro Cells Article Tumor-infiltrating T cell rescue by programmed cell death receptor-1 (PD-1)/PD-1 ligand-1 (PD-L1) immune checkpoint blockade is a recommended treatment for malignant diseases, including metastatic non-small-cell lung cancer (mNSCLC), malignant melanoma (MM), head and neck, kidney, and urothelial cancer. Monoclonal antibodies (mAbs) against either PD-1 or PD-L1 are active agents for these patients; however, their use may be complicated by unpredictable immune-related adverse events (irAEs), including immune-related pneumonitis (IRP). We carried out a retrospective multi-institutional statistical analysis to investigate clinical and biological parameters correlated with IRP rate on a cohort of 256 patients who received real-world treatment with PD-1/PD-L1 blocking mAbs. An independent radiological review board detected IRP in 29 patients. We did not find statistical IRP rate correlation with gender, tumor type, specific PD-1 or PD-L1 blocking mAbs, radiation therapy, inflammatory profile, or different irAEs. A higher IRP risk was detected only in mNSCLC patients who received metronomic chemotherapy +/− bevacizumab compared with other treatments prior PD-1/PD-L1 blockade. Moreover, we detected a strong correlation among the IRP rate and germinal expression of HLA-B*35 and DRB1*11, alleles associated to autoimmune diseases. Our findings may have relevant implications in predicting the IRP rate in mNSCLC patients receiving PD-1/PD-L1 blockade and need to be validated on a larger patient series. MDPI 2020-08-25 /pmc/articles/PMC7564884/ /pubmed/32854442 http://dx.doi.org/10.3390/cells9091964 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Correale, Pierpaolo
Saladino, Rita Emilena
Giannarelli, Diana
Sergi, Andrea
Mazzei, Maria Antonietta
Bianco, Giovanna
Giannicola, Rocco
Iuliano, Eleonora
Forte, Iris Maria
Calandruccio, Natale Daniele
Falzea, Antonia Consuelo
Strangio, Alessandra
Nardone, Valerio
Pastina, Pierpaolo
Tini, Paolo
Luce, Amalia
Caraglia, Michele
Caracciolo, Daniele
Mutti, Luciano
Tassone, Pierfrancesco
Pirtoli, Luigi
Giordano, Antonio
Tagliaferri, Pierosandro
HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
title HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
title_full HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
title_fullStr HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
title_full_unstemmed HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
title_short HLA Expression Correlates to the Risk of Immune Checkpoint Inhibitor-Induced Pneumonitis
title_sort hla expression correlates to the risk of immune checkpoint inhibitor-induced pneumonitis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7564884/
https://www.ncbi.nlm.nih.gov/pubmed/32854442
http://dx.doi.org/10.3390/cells9091964
work_keys_str_mv AT correalepierpaolo hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT saladinoritaemilena hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT giannarellidiana hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT sergiandrea hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT mazzeimariaantonietta hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT biancogiovanna hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT giannicolarocco hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT iulianoeleonora hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT forteirismaria hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT calandruccionataledaniele hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT falzeaantoniaconsuelo hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT strangioalessandra hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT nardonevalerio hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT pastinapierpaolo hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT tinipaolo hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT luceamalia hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT caragliamichele hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT caracciolodaniele hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT muttiluciano hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT tassonepierfrancesco hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT pirtoliluigi hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT giordanoantonio hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis
AT tagliaferripierosandro hlaexpressioncorrelatestotheriskofimmunecheckpointinhibitorinducedpneumonitis